Business Wire

NY-REVBITS

22.5.2023 15:16:25 CEST | Business Wire | Press release

Share
RevBits Completes Development for its Privileged Access Management Solution to be Fully Deployable in a True Air Gapped Environment

RevBits announces that it has successfully completed the architectural development of its privileged access management solution for deployment in a true air gapped environment.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230522005003/en/

RevBits Privileged Access Management (RB/PAM) is an advanced access management solution that includes seven modules and extensive session logging that captures keystrokes and video. These unique access control capabilities and multi-module offerings reduce vendor relationship management efforts and increase access management safeguards.

RevBits PAM has two U.S. patents - a browser-based zero-knowledge encryption and authentication authority that extends to various hardware security solutions.

RevBits PAM modules:

Privileged Access Management - regulates access to critical resources, captures keystrokes, and video records all privileged sessions.

Privileged Session Management - provides keystroke and query logging for all sessions through the solution's Jump Server.

Password Management - extends authentication security with hardware security modules, USB tokens, smart cards, near-field communications, and RFID.

Service Account Management - scans and onboards service accounts and scheduled tasks for IIS web applications.

Key Management - allows users to easily generate and store encryption keys.

Certificate Management - reports all expired or soon-to-expire certificates and vulnerable implementations of SSL.

CI/CD Integration - the CI/CD module plugs into your current platform and unlocks the capabilities of secure secret management across the CI/CD lifecycle, allowing for easy management of CI/CD users, credentials, and assets.

Defining Air Gap:

Techopedia: "An air gap is a security measure that isolates a digital device component or private local area network (LAN) from other devices and networks, including the public internet. An air gap is also known as an air wall, and the strategy of using air gaps to protect critical data is also known as security by isolation.

Air gaps are used to protect critical computer systems and the data they store from malware, keyloggers, ransomware, and other types of unauthorized access. This strategy seeks to ensure the total isolation of a given system electromagnetically, electronically, and physically."

RevBits Privileged Access Management – our Air Gap capability:

Inside the air gap environment sit servers and assets critical to the organization. As important as it is to protect against malware and ransomware attacks, it is equally important to protect the data on those servers from malicious acts and theft in an air gap environment.

RevBits Privileged Access Management is fully featured in an air gapped environment allowing for complete server security and data protection. Server access is monitored through extensive session monitoring, including video recording and keystroke logging.

About RevBits

Established in 2018, RevBits is a comprehensive cybersecurity company dedicated to providing customers with superior protection and service. RevBits delivers protection against the most sophisticated cyber threats companies face by offering multiple advanced security capabilities that can be administered through a unified security platform. RevBits is headquartered in Mineola, NY, with offices in Princeton, NJ; Boston, MA; London, England; and Antwerp, Belgium. For more information please visit RevBits.

RevBit's complete solution suite offerings are RevBits Endpoint Security, RevBits Email Security, RevBits Privileged Access Management, RevBits Zero Trust Network, and RevBits Deception Technology. For customers running more than one RevBits solution, the administration is managed through RevBits Cyber Intelligence Platform, a unified, single-pane environment that curates, correlates, and alerts to threats while delivering intelligence for a quick administrative response. RevBits Cyber Intelligence Platform integrates with all common SIEMs.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230522005003/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release

Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around

Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release

Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5

HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release

HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye